8 recruiting. 8 Phase 2, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 8 |
| Phase 3 | 8 | Recruiting 8 |
Follow Haematological Malignancy: new trials by email Literature Review of Haematological Malignancy trials Research Report on Haematological Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations Trastuzumab, Pertuzumab - Haematological Malignancy, Colorectal Neoplasms | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-07 | 2025-12-02 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
Hematologic Neoplasms (8) · Neoplasms (8) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Glioma (4) · Lymphoproliferative Disorders (4) · Colorectal Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Erdheim-Chester Disease (2) · Laryngeal Neoplasms (2) · Lymphoma (2) · Melanoma (2) · Multiple Myeloma (2) · Neuroblastoma (2)
Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Neuroectodermal Tumors (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Gastrointestinal Diseases (4)
Trastuzumab (2) · Vemurafenib (2) · alectinib (2) · capmatinib (2) · cobimetinib (2) · dabrafenib (2) · entrectinib (2) · pertuzumab (2) · trametinib (2) · Amoxicillin (1) · Ciprofloxacin (1) · Clavulanic Acid (1) · Immunoglobulins (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · atezolizumab (1)
Cancer Research UK (7) · Monash University (1)
United Kingdom (7) · Australia (1)
Matthew Krebs, Dr (6) · Matthew Krebs (1) · Prof Erica Wood (1) · Prof Zoe McQuilten (1)